ArticleNeurobiology of aging2024
Associations between recall of proper names in story recall and CSF amyloid and tau in adults without cognitive impairment.
Open access · greenAbstract read
In one paragraph
Article in Neurobiology of aging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 6 citations in OpenAlex.
- A multiverse analysis of the logical memory test and plasma biomarkers of Alzheimer's disease.Cortex; a journal devoted to the study of the nervous system and behavior · 2026Article
- Validation of longitudinal change in proper name recall with pTau217 as a marker of early cognitive decline in cognitively unimpaired adults at risk for Alzheimer's disease dementia.Journal of Alzheimer's disease : JAD · 2026Article
- The Clinical Utility of the Cognitive Impairment Screening Test (CIST).Dementia and neurocognitive disorders · 2026Article
- Enhanced sensitivity to plasma p-tau217 with proper names recall in the preclinical Alzheimer's cognitive composite.Brain communications · 2026Article
- Development of language composites for enhanced sensitivity to multiple plasma biomarkers.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Amyloid and tau may moderate practice effects in semantic and episodic memory in a cognitively unimpaired at-risk sample.Brain communications · 2025Article
- Sex differences in story recall decline in preclinical Alzheimer's disease.Brain communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 7 institutions in 5 countries.
Madeline R HaleDepartment of Communication Sciences and Disorders, University of Wisconsin-Madison, Madison, WI, USA.
Rebecca LanghoughAlzheimer's Disease Research Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA; Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; Wisconsin Alzheimer's Institute, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.
Lianlian DuSchool of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA; Wisconsin Alzheimer's Institute, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.
Bruce P HermannDepartment of Neurology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.
Carol A Van HulleAlzheimer's Disease Research Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; Wisconsin Alzheimer's Institute, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; Division of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.
Margherita CarboniRoche Diagnostics International Ltd, Rotkreuz, Switzerland.
Gwendlyn KollmorgenRoche Diagnostics GmbH, Penzberg, Germany.
Kristin E BascheAlzheimer's Disease Research Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.
Davide BrunoSchool of Psychology, Liverpool John Moores University, Liverpool, UK.
Leah Sanson-MilesDepartment of Communication Sciences and Disorders, University of Wisconsin-Madison, Madison, WI, USA.
Erin M JonaitisAlzheimer's Disease Research Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA; Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; Wisconsin Alzheimer's Institute, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.
Nathaniel A ChinAlzheimer's Disease Research Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA; Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; Wisconsin Alzheimer's Institute, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; Division of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA; VA Geriatric Research, Education and Clinical Center (GRECC), William S. Middleton Memorial Veterans Hospital, Madison, WI, USA.
Ozioma C OkonkwoSchool of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.
Barbara B BendlinAlzheimer's Disease Research Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA; Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; Wisconsin Alzheimer's Institute, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; Division of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA; VA Geriatric Research, Education and Clinical Center (GRECC), William S. Middleton Memorial Veterans Hospital, Madison, WI, USA.
Cynthia M CarlssonAlzheimer's Disease Research Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA; Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; Wisconsin Alzheimer's Institute, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; Division of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.
Henrik ZetterbergDepartment of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK; UK Dementia Research Institute at UCL, London, UK; Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Tobey J BetthauserAlzheimer's Disease Research Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA; Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; Division of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA.
Sterling C JohnsonAlzheimer's Disease Research Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA; Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; Wisconsin Alzheimer's Institute, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; Division of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin School of Medicine & Public Health, Madison, WI, USA; VA Geriatric Research, Education and Clinical Center (GRECC), William S. Middleton Memorial Veterans Hospital, Madison, WI, USA.
Kimberly D MuellerDepartment of Communication Sciences and Disorders, University of Wisconsin-Madison, Madison, WI, USA; Alzheimer's Disease Research Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA; School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA; Wisconsin Alzheimer's Institute, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA. Electronic address: kdmueller@wisc.edu.
University of Wisconsin–Madison · USWilliam S. Middleton Memorial Veterans Hospital · USGeriatric Research Education and Clinical Center · USLiverpool John Moores University · GBRoche Pharma AG (Germany) · DERoche (Switzerland) · CHUniversity of Gothenburg · SE
Funding
University of Wisconsin Institute for Clinical and Translational ResearchUL1TR002373 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI ELIZABETH S BURNSIDE, Allan R. Brasier · 2017 to 2026
$75.9MWisconsin Registry for Alzheimer's Prevention: Sex Differences in DNA MethylationR01AG027161 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Nathaniel Ark Chin, Sterling C Johnson · 2007 to 2026
$35.6MInstitutional Clinical and Translational Science AwardUL1TR000427 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI DREZNER, MARC KENNETH · 2012 to 2016
$32.2MAfrican Americans Fighting Alzheimer’s in Midlife (AA-FAIM)R01AG054059 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI CAREY E GLEASON · 2016 to 2026
$15.3MAlzheimer's Disease Connectome ProjectUF1AG051216 · NIA · MEDICAL COLLEGE OF WISCONSIN · PI BENDLIN, BARBARA BRIGITTA, LI, SHI-JIANG · 2016 to 2019
$5.8MWhite matter degeneration: biomarkers in preclinical Alzheimer's DiseaseR01AG037639 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI BENDLIN, BARBARA BRIGITTA · 2012 to 2023
$5.3MLongitudinal Investigation of Cardiorespiratory Fitness and AD Biomarkers in an At-Risk CohortR01AG062167 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI OKONKWO, OZIOMA C · 2019 to 2023
$4.5MNovel Story Recall Measures as Indicators of Cognitive Decline Associated with Alzheimer's Disease and Related Disorders Biomarkers: A Collaborative Study of Existing DataR01AG070940 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Kimberly D Mueller · 2021 to 2026
$2.8MStatin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for ADR01AG031790 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI CARLSSON, CYNTHIA M · 2009 to 2013
$1.6MWhite matter degeneration: biomarkers in preclinical Alzheimer's DiseaseR56AG037639 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI BENDLIN, BARBARA BRIGITTA · 2017 to 2017
$759kNCATS NIH HHS UL1 TR000427NCATS NIH HHS UL1 TR002373NIA NIH HHS R01 AG027161NIA NIH HHS R01 AG031790NIA NIH HHS R01 AG037639NIA NIH HHS R01 AG054059NIA NIH HHS R01 AG062167NIA NIH HHS R01 AG070940NIA NIH HHS R56 AG037639NIA NIH HHS UF1 AG051216
Abstract
Neuropsychological measures sensitive to decline in the preclinical phase of Alzheimer's disease are needed. We previously demonstrated that higher amyloid-beta (Aβ) assessed by positron emission tomography in adults without cognitive impairment was associated with recall of fewer proper names in Logical Memory story recall. The current study investigated the association between proper names and cerebrospinal fluid biomarkers (Aβ
Indexed as
Alzheimer DiseaseCognitive DysfunctionAmyloid beta-PeptidesBiomarkersDisease ProgressionHumansLongitudinal StudiesPeptide Fragmentstau ProteinsAmyloid beta-PeptidesBiomarkersPeptide Fragmentstau ProteinsCerebrospinal fluidEarly detectionPreclinical Alzheimer’s diseaseProper namesStory recall
Identifiers
What Socratic holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.